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Background: Although government-funded specialist smoking cessation services in England offer advice and
support to smokers motivated to quit, only a small proportion of smokers make use of this service. Evidence
suggests that if smokers are proactively and personally invited to use services, use will be higher than with a
standard referral made by health professionals. Computer-based systems generating personalised tailored
communications also have the potential to engage with a larger proportion of the smoking population. In this
study smokers are proactively invited to use the NHS Stop Smoking Service (SSS), with a personal computer-tailored
letter and the offer of a no-commitment introductory session designed to give more information about the service.
The primary objective is to assess the relative effectiveness on attendance at the NHS SSS, of proactive recruitment
by a brief personal letter, tailored to individual characteristics, and invitation to a taster session, over a standard
generic letter advertising the service.
Method/design: This randomised controlled trial will recruit smokers from general practice who are motivated to
quit and have not recently attended the NHS SSS. Smokers aged 16 years and over, identified from medical records
in participating practices, are sent a brief screening questionnaire and cover letter from their GP. Smokers giving
consent are randomised to the Control group to receive a standard generic letter advertising the local service, or to
the Intervention group to receive a brief personal, tailored letter with risk information and an invitation to attend a
‘Come and Try it’ taster session. The primary outcome, assessed 6 months after the date of randomisation, is the
proportion of people attending the NHS SSS for at least one session. Planned recruitment is to secure 4,500
participants, from 18 regions in England served by an NHS SSS.
Discussion: Personal risk information generated by computer, with the addition of taster sessions, could be widely
replicated and delivered cost effectively to a large proportion of the smoking population. The results of this trial will
inform the potential of this method to increase referrals to specialised smoking cessation services and prompt more
quit attempts.
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The prevalence of smoking in the UK has fallen from
25% to 22% and 23% to 21% between 2005 and 2008 in
men and women, respectively [1]. While government
targets to reduce smoking prevalence have been
achieved [2], there is no room for complacency. Smok-
ing remains a major cause of ill health and mortality,
accounting for approximately 18% of all deaths in adults
aged over 35 years in 2007 [3]. Furthermore, national
statistics from 2008 figures show a widening gap in
smoking prevalence between those in professional and
managerial occupations, and routine and manual work-
ers; 29% of the latter still smoke, rising to 42% of those
currently not employed [1].
Government-funded specialist smoking cessation ser-
vices were implemented in 1999 in Health Action Zones,
and were rolled out throughout England in 2000 [4].
These services offer intensive advice and support to
smokers motivated to quit, in group or one-to-one ses-
sions. However, most smokers will not attend formal
cessation programmes, preferring to quit on their own,
consequently such programmes are consistently under-
used [5-8]. In 2007, 74% of current smokers in Great
Britain reported that they want to quit, and 31% had
made an attempt to quit in the previous year [9]. In
2001 to 2002, 2.01% of the adult smoking population in
England set a quit date using the National Health Ser-
vice (NHS) Stop Smoking Services (SSS) [10], and even
now this figure is estimated to be < 5% [11-13]. Thus,
despite a desire to quit, only a small proportion use the
free service provided by the NHS [14].
A wide range of factors, such as lack of availability and
accessibility, perceived inappropriateness of the service,
a perception that help is not necessary, or a sense of a
lack of empathy from health professionals, as well as a
lack of readiness to quit, will bar smokers from seeking
help [15,16]. The literature also suggests that many smo-
kers are unaware of, or have insufficient knowledge of or
inadequate information about the services available
[16,17] and this lack of knowledge can also lead to the
belief that ‘it wouldn’t help me anyway’ [16].
Health professionals are guided to offer brief advice
and refer smokers to the services, but the percentage of
smokers receiving such advice is small, and only 9%
were referred to the cessation services in 2007 [3].
Moreover, these smokers are generally expected to
follow-up their referral and contact the service them-
selves to make the appointment. Lichtenstein [7] evalu-
ated an intensive and standardised referral protocol,
employing a more proactive method of recruitment and
referral by inviting smokers to an intervention with a
strong referral message to the service and offering infor-
mation about what attendance at the service would
involve. This intervention included an assessment,measurement of expired-air carbon monoxide (CO) level
with an interpretation, a 10-min video of a stop smoking
group program featuring former successful group mem-
bers, a voucher fee waiver, and immediate scheduling of
the smoker for the group. With this intervention, 11.3%
of smokers attended the first session of the cessation
programme, compared with 0.006% of the control group
who received brief advice only.
While recruitment methods to cessation services gen-
erally employ a reactive approach, in which smokers are
expected to seek out and approach the service [16], evi-
dence suggests that if smokers are proactively and per-
sonally invited to use the services, the resultant use will
be higher than standard referral by health professionals,
or open advertising. In a study exploring the acceptabil-
ity of proactive contact offering cessation services to
smokers, 92.8% found it acceptable for the health service
to contact people to offer assistance, and 55.7% said they
were likely to take up the offer of individual counselling
[16]. This could be an overestimation of actual take-up
of the service, but suggests that proactive contact is ac-
ceptable and that smokers are open to intensive
counselling.
In a study by Murray and colleagues [11,18], general
practices identified all patients who were recorded as
current smokers or with no status recorded, and pro-
actively informed them by letter about the stop smoking
services, giving the option of being contacted by an ad-
visor. The proportion of current smokers expressing
interest was 13.8%, suggesting that more than the
current 5% of the smoking population setting quit dates
within the NHS are interested in receiving help. Hence,
novel methods of marketing to engage interested smo-
kers are needed in order to encourage use of the ser-
vices. Furthermore, general practices were randomized
to an intervention group or to a control group. Smokers
in practices allocated to the intervention group indicat-
ing that they would like to speak to an advisor were con-
tacted within 8 weeks by a researcher trained as an
advisor and offered advice and an appointment. Smokers
in control group practices received no further contact.
Murray reported a 7.7% increase in smokers using the
NHS SSS in the intervention group over the control
group at the 6-month follow-up, and an increase of 1.8%
in validated abstinence in those smokers requesting con-
tact, over the control group (4% vs. 2.2%).
The study by Murray and colleagues [18] was the
first to assess a proactive method of recruitment to
attract smokers into the services. However more per-
sonal methods of recruitment such as the use of tailored
self-help materials, intended to meet the needs of one
specific person, based on characteristics unique to that
person [19] could further enhance recruitment. The de-
velopment of these materials has enabled the generation
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ing cessation [20]. A computer-based system developed
by two of the investigators (HG and SS) to generate
individually-tailored feedback reports designed to en-
courage and help smokers to quit demonstrated a posi-
tive effect when used as an adjunct to telephone
counselling (via the national Quitline) [21], a finding
consistent with other studies [22]. These computer-
based systems offer a method for further personalising
communications to patients and have the potential to
engage with and recruit a larger proportion of the smok-
ing population.
In this study we extend the work of Murray and col-
leagues [18] by providing a more intensive intervention
using computer-tailored feedback to deliver personalised
risk information to invite and encourage people to at-
tend the NHS SSS. In addition smokers are offered a no-
commitment taster session designed to inform them
about the service and what it offers.
Intensive clinical treatment is particularly important
for: (1) smokers at high risk because of chronic condi-
tions; and (2) heavily dependent smokers who have been
unsuccessful in previous attempts [5]. Furthermore, a
long-term aim of the NHS SSS is to help disadvantaged
people to stop smoking. However, government targets to
reduce smoking prevalence in the UK in manual groups
to 26% by 2010 have not been reached [23]. Thus, as
part of this strategy the delivery of cessation services to
poorer communities has been a priority [10]. While the
services have succeeded in attracting smokers from
disadvantaged areas [10,15,24], unacceptable smoking-
related health inequalities persist [1]. An advantage of
the proactive recruitment method is the ability to target
at risk groups. Smokers from the most disadvantaged
areas are more interested in receiving help than smokers
from areas of low deprivation [11], thus more attractive
methods to inform and engage this group are needed,
including the use of medical information on chronic ill-
nesses and high dependence to tailor our communica-
tions with smokers.
It is possible that by using methods of direct mail con-
tact, smokers not ready or motivated to quit may be
encouraged to attend the SSS, but would be less likely to
quit than self-referred patients [14]. Traditionally smo-
kers with an intention to quit in the next 2 weeks are
targeted in the NHS for attendance at specialist clinics,
but planning to quit in the near future should not be
taken as the only indicator of interest in quitting. Studies
have shown that smokers stating that they have no plans
to quit have taken part in cessation programmes [25],
and evidence from a recent trial suggests that proactive
recruitment can successfully engage smokers with no
immediate plans to quit in quitting activity [26]. There is
also evidence of smokers quitting without entering apreparation stage or planning to quit [27]. Thus, in this
study, we include those whose intention to quit is more
distant, and those who express an interest in receiving
help to quit.
The primary objective of the study is to assess the rela-
tive effectiveness on attendance at the NHS services of
at least one session, of proactive recruitment by a brief
personal letter, tailored to individual characteristics
available in medical records, and invitation to a taster
session to provide information about the NHS services,
over a standard generic letter advertising the service.
Secondary objectives aim to: (1) assess the relative
effectiveness of the two recruitment methods on bio-
chemically validated 7-day point-prevalent abstinence
rates at the 6-month follow-up; (2) compare the cost-
effectiveness of the two invitation methods; (3) assess
the relative effectiveness on prolonged abstinence mea-
sured by self-report of not smoking for periods of
7 days to 24 weeks at the 6-month follow-up; (4) as-
sess the number of smokers attending the taster ses-
sion and the number of smokers completing the
6-week NHS smoking cessation course; (5) assess the
number of quit attempts made and any reduction in
daily cigarette consumption; (6) determine predictors
of attendance at the services, and of attendance at the
taster sessions (in the Intervention group); (7) explore
reasons for non-attendance and barriers to attendance
at the NHS SSS; and (8) explore the effectiveness of
the intervention by socioeconomic status, and social
deprivation.Method
Design and setting
The study is a randomised controlled trial (RCT) of a
primary care population, utilising general practices to
recruit smokers to the NHS SSS. Conducted in two
stages, the pilot phase, in two areas served by a NHS
SSS, aimed to ascertain rates of recruitment, the rate
of uptake in attendance at the taster session, and to es-
tablish that the difference in uptake of smoking cessa-
tion services between the Intervention and Control
groups is greater than zero, before proceeding to the
full trial in a further eight areas that are representative
of the English SSS.
The trial is conducted as a collaboration between
University College London (UCL) and the Universities
of Cambridge and York. It is being coordinated from
UCL and is run through the UK Clinical Research Col-
laboration (UK CRC) registered UCL Clinical Trials
Unit (PRIMENT). Ethical approval for the study was
granted by the South West London Research Ethics
Committee, and R & D approval will be obtained from
all participating SSSs.
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Ultimately this study aims to help participants to stop
smoking, and risks for trial participants are minimal.
Patients are informed in the patient information leaflet
of the benefits of attending the NHS treatment services
in order to obtain help to change their smoking behav-
iour to be of benefit to their health. It is unlikely that
there will be any adverse effects for trial participants.
However, anyone experiencing concern about their
smoking habit as a result of the communication has the
opportunity to attend the services to obtain help. Any-
one experiencing any other kind of distress as a result of
the assessment or intervention is referred to their gen-
eral practitioner (GP) or practice counsellor.
All participants included in the trial will have given
their written consent to take part, and for their data to
be used in communications to them, and for any subse-
quent monitoring data obtained as a result of their use
of the NHS services to be used for research purposes.
Target population
The target group is smokers motivated to quit who have
not recently attended the NHS SSSs.
Recruitment procedure
The Primary Care Research Network (PCRN) comprises
eight clinician-led Local Research Networks, providing
comprehensive geographical coverage of England. Team
members work with GP practices to facilitate the in-
volvement of staff and patients in clinical studies. We
are working with these networks to identify practices in
selected SSS areas, using Census data and Indices of
Multiple Deprivation (IMD) (the Government’s official
measure of multiple deprivation at small area level
which provides a relative ranking of areas across
England according to their level of deprivation) to select
more practices in areas of high deprivation and of large
ethnic communities to ensure full representation of
smokers most in need of help, and to maximise the gen-
eralisability of the results.
Participating practices identify all smokers aged 16
years and over from their medical records. After screen-
ing by GPs to exclude anyone deemed to be unsuitable
for the project (for example, severely or terminally ill) all
remaining persons on the list are sent a brief screening
questionnaire with a cover letter from their GP. A par-
ticipant information leaflet describing the research is
included, with a consent form to participate in the trial.
Participants are also asked to provide consent for the re-
lease of relevant data from their attendance at the NHS
services to the researchers, used to validate attendance
and quit rates. The questionnaire data is used to assess
the criteria for inclusion in the trial, and to provide in-
formation for the tailored letter. Patients have the optionof returning the questionnaire to update their smoking
status in their records only and not participating in the
trial. A Freepost envelope is included for the return of
the questionnaire to the practice, and non-responders
are sent a reminder and duplicate questionnaire 3 weeks
after the first mailing. All smokers returning the signed
consent form and eligible to participate are randomised
to the Intervention or Control group.
Inclusion/exclusion criteria
All current smokers willing to participate and returning
the signed consent form, aged 16 years and over, able to
read English, motivated to quit, and have not recently
attended the NHS services are eligible for inclusion in
the study. For the purposes of this research, motivation
to quit is defined as answering ‘yes’ to either or both of
the following questions: (1) are you seriously thinking of
quitting in the next 6 months; and (2) would you think
of quitting if appropriate help were offered at a convenient
time and place. Exclusion criteria are minimal because the
aim is to recruit all smokers into the services. However,
smokers younger than 16 years old are excluded because
of the need for parental consent to participate for this
age group. Also excluded are any patients identified
who are considered by the GP to be unsuitable for the
project, for example, severely or terminally ill.
Planned interventions
Control group
Participants are sent a standard generic letter from the
GP practice advertising the local NHS SSS and asking
the smoker to contact the service to make an appoint-
ment to see an advisor.
Intervention group
Participants receive the following:
(1) a brief motivational letter sent from the GP that
includes information specific to the patient. The letter is
personalised and tailored using known characteristics
(age and gender), plus information obtained from the
screening questionnaire (dependence, previous quit
attempts). Information from medical records about the
patient’s general health status and about chronic condi-
tions (for example, heart disease, diabetes, lung disease)
is also used to provide risk information and to offer help
to improve their condition by quitting smoking. The
amount of tailoring is maximised within the constraints
of the short screening questionnaire and brief letter. The
content of the letter has been developed in collaboration
with GPs and primary care experts with knowledge of
medical information available in records.
(2) an invitation and an appointment to attend a
‘Come and Try it’ taster session to find out more about
the services. This taster session is run by advisors from
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vice and help offered by the NHS service is based on evi-
dence, with a higher likelihood of success; information
about the services offered, that is one-to-one or group
sessions, the length of a session and the length of the
course, nicotine replacement therapy (NRT) or other
pharmacotherapy, as well as behavioural support; infor-
mation about what to expect when they attend and the
content of advice (for example, help dealing with weight
gain, the correct use of NRT, depression, expected out-
comes); the expectations of the service, that is willing-
ness to set a quit date and a rule of not smoking a single
puff after the quit date; a measurement of CO level with
an interpretation; a 5-min video showing group and
one-to-one sessions in progress, and testimonials from
previous successful attendees, produced by UCL Media
Services in collaboration with Camden SSS; the oppor-
tunity to ask questions about the service.
Each SSS runs eight to twelve taster sessions. Approxi-
mately 50 participants are invited to each session which
lasts about 1 hour and at the end of the taster session
attendees are encouraged to sign up to a group or one-
to-one session at the SSS at a time convenient to them.
A standard protocol for the taster sessions was devel-
oped in consultation with one of the co-investigators
(SG) and the NHS Centre for Smoking Cessation and
Training (NSCTC) to conform to national guidelines
[28]. Three to four advisors in each SSS, already trained
to give smoking cessation advice in group and one-to-
one sessions, are trained to lead the taster sessions
according to this protocol, standardised on the under-
standing that, while services may differ in the way they
are organised, the protocols for delivering advice are uni-
form. In order to achieve standardisation to the protocol,
the training is manualised and includes an explanation
and clarification of the study protocol and procedures.
The same advisors will lead all sessions in each SSS. The
taster sessions are audio-recorded, with the consent of
the attendees to ensure fidelity to the protocol.
The intervention is further enhanced by the addition
of a repeated personal letter with a further invitation
sent 3 months after the original to all participants who
fail to attend a taster session. This is consistent with
recommendations made by Lichtenstein [7], who pro-
posed that, with repeated advice over time, a greater
proportion will be likely to respond.
The standard generic letter and an example of the per-
sonal risk letter and taster session invitation are included
in the Additional Material files (see Additional file 1).
Data management and randomisation
The patient-level data collected in this trial comprise in-
formation downloaded from practice records, and infor-
mation provided by participants on the consent form,the baseline questionnaire, and in the follow-up tele-
phone interviews.
The practice record information is used to: (1) gener-
ate letters inviting patients to participate in the trial, sent
from the practice; and (2) generate the tailored and gen-
eric letters, also sent from the practice. Purpose-written
programs written in Visual Basic for Applications (VBA)
which read and write Excel and Word files are used to
generate these letters.
Procedure for generating letters
Data from medical records are downloaded to an Excel
spreadsheet and stored on a practice computer. The data
are backed up on memory sticks, or on another practice
computer. Using a computer program written in VBA,
stored on a laptop, these data are used to create a file of
invitation letters in MS Word. Potential participants who
live in the same household are identified by the program
to ensure that only one person from the same household
receives a screening questionnaire. The file of invitation
letters is copied to a practice computer and a back-up
disk and deleted from the laptop. Each patient returning
the completed questionnaire, and willing and eligible to
participate, is coded as ‘participant’ on the Excel spread-
sheet and the name and address information checked
and updated if necessary on the spreadsheet against the
consent form. Participants are exported to a new spread-
sheet. The questionnaire data necessary to produce the
intervention letter are coded into the new spreadsheet.
A second computer program, also written in VBA and
stored on a laptop: (1) allocates to the participant a
study ID number; (2) randomises participants to the
Control or Intervention group; and (3) combines the
data from the baseline questionnaire and medical
records with the correct messages from a message li-
brary written using Microsoft Word, to generate two
Word files, containing the tailored letters for interven-
tion participants and the generic letters for control parti-
cipants, respectively.
Patients who return the questionnaire with written
consent, but who are not eligible to take part in the
study are sent a letter thanking them for responding and
informing them that they do not fit the study criteria,
and patients who return questionnaires outside the time-
frame for processing are sent a similar letter informing
them that the recruitment period is ended. Both letters
are sent from the GP practice and contain information
about the local NHS Stop Smoking Service, advising the
smoker to contact the service for more information or
to speak to an advisor.
Security
This procedure is managed within each practice by prac-
tice and research staff. All data files and back-up media
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been randomised and the tailored and generic letters
have been generated. At this point proprietary encryp-
tion software (Truecrypt) is used to create two separate
encrypted files containing: (1) personal information (that
is, name and address); and (2) medical and questionnaire
information (including information on medical condi-
tions from the patient records). These files are copied to
a CD and taken to the study centre at UCL where they
are copied and stored on separate encrypted volumes on
a UCL server. This is the only point in the procedure at
which electronic data leave the practice.
The consent forms and questionnaires are also taken
from the practice to the study centre and stored in
locked filing cabinets after the questionnaires have been
scanned to enter the remaining data, also stored on
encrypted volumes on a UCL server.
All data files are deleted from the laptop before leaving
the practice. The only files kept on the laptop are the
purpose written computer programs, the message li-
brary, the randomisation tables, the practice letterhead
file, and the file containing GP signature.
The files from different practices will later be merged
into a single file of personal information and a single file
of medical and questionnaire information stored on sep-
arate encrypted volumes at UCL. A subset of this infor-
mation will be used by research interviewers to conduct
the follow-up telephone interviews. All electronic data
will be stored on encrypted volumes on a UCL server.
This is a highly secure data management system that
avoids the need for web-based transfer of electronic
patient-level data.
Randomisation
Randomisation, at the level of the study participant, is
embedded into the computer program according to an
externally constructed randomisation plan, using per-
muted blocks. Participants are randomised in the ratio
3:2 (intervention:control) within practice, stratified by
gender, and using a block size of 5. For each practice, a
computer program is run to create two randomisation
tables, one for men and one for women. Each table con-
sists of 500 rows. In one column, there is a sequence of
2 s and 1 s in blocks of 5 (for example 1,1,2,2,1). This se-
quence is created by listing all possible permutations of
three 1 s and two 2 s (10 in all), then repeatedly select-
ing one permutation at random (with replacement) and
adding each selection to the sequence. This procedure
uses the random number generating function rnd in
Microsoft VBA. For each table, the Randomize state-
ment is used to initialize the random number generator
with a seed based on the system timer. Having created
the tables for a given practice, another computer pro-
gram is used to allocate participants from that practiceto condition by selecting the first unused code (1 or 2)
from the table for men or the table for women, depend-
ing on the participant’s gender, and then marking that
code as used. If the information about gender is missing
for a participant, the randomisation table to be used is
selected at random. Any imbalances will be controlled
for in the statistical analysis using covariates that are
identified prior to examining the trial data. The use of a
computer program that enforces randomisation after
consent and baseline data entry ensures that conceal-
ment is preserved and differential entry prevented.
Methods to protect against other sources of bias
By randomising at the level of participant rather than by
practice, there is a slight risk of contamination by com-
munication between patients at the same practice allo-
cated to different conditions. While we consider this risk
to be low, the following measures reduce the risk fur-
ther: identify potential participants who live in the same
household and ensure that only one person from the
same household receives a screening questionnaire;
monitor attendance at the taster sessions, to ensure that
anyone attending who has not received an invitation is
recorded and checked against participants in the Control
group; measure the amount of contamination at follow-
up by: (i) asking participants whether they have attended
a taster session, and if not, whether they personally
know or have spoken to anyone else who has been
invited to the NHS stop smoking services; and (ii) valid-
ation of self-report by keeping a record of attendance at
the taster sessions.
It is not possible to blind participants to the receipt of
a personally tailored letter, and invitation to a taster
session. While the personal letter is generated in the
practice by Research Assistants, the remainder of the re-
search team in all cases are blind to the allocation of the
participant, which will be enforced by the data manage-
ment. In follow-up interviews, the interviewer will be
blinded to the allocation of the respondent in order to
avoid bias in outcome assessment.
External validity of the sample is estimated by compar-
ing data on non-responders to the invitation to partici-
pate with that of responders. Data are anonymised
by removing names, addresses, and NHS numbers of
non-responders from the database. Gender, date of
birth (converted to age), and postcode (converted to
an IMD score via GeoConvert) are used to calculate
means within each practice and compare to those of
responders.
Duration of treatment period and follow-up
The process from the searching of records to identify
smokers to the completion of the follow-up takes ap-
proximately 38 weeks. Recruitment takes place over
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search team to process responses. Four taster sessions
are held in each area, three to coincide with the visits to
process responses, and a final one to which all remaining
non-attenders are invited. Figure 1 shows detail of the
timing of assessments, intervention, and follow-up.
Measures
Baseline measures
Lichtenstein [7] found that readiness, motivation, and
dependence were positively related to follow through,
readiness defined as smokers planning to quit in the
next 6 months. The baseline screening questionnaire
therefore uses the definitions and measures of motiv-
ation and readiness used by Lichtenstein [7] in order to
provide the right encouragement to those who might be
prompted to quit. In addition to screening for inclusion
criteria, also assessed are demographics, dependence on
nicotine (number of cigarettes per day and time from
waking to first cigarette), smoking history (age started
and previous quit attempts), and determination to quit.
Outcome measures
Primary The proportion of people entering the smoking
cessation service (that is, attending the first session of a
6-week course) over a period of 6 months from the receipt
of the invitation letter. Self-reported attendance data will
be validated by records of attendance at the NHS SSSs.
Secondary Secondary outcome measures are: (1) 7-day
point prevalent abstinence at the 6-month follow-up,
validated by salivary cotinine for all participants report-
ing abstinence in both the Intervention and Control
groups; (2) prolonged periods of abstinence of 7 days toWeek 1 to 3 Week 5 to 11 Weeks 7 to 13 Week 
Search records in 
general practices
Baseline 
screening 
questionnaire with 
covering letter 
sent to identified
smokers
Baseline 
screening 
questionnaire with 
covering letter 
sent to non-
responders
Screening 
questionnaires 
returned to 
practice
Data entered and 
consenting 
participants 
randomised to 
Intervention or 
Control group
Standard or 
tailored letter and 
invitations sent
Taster sessions in 
SSS held
Reminder 
letter and 
invitations
non-attend
Figure 1 Timing of assessments, intervention, and follow-up.24 weeks measured by self-report; (3) self-reported
changes in daily cigarette consumption, quit attempts,
and changes in motivation and intention to quit in con-
tinuing smokers; (4) use of NRT or Zyban or Champix
and other smoking cessation aids; and (5) the number
completing the 6-week NHS course.
Process measures Process measures are: (1) the number
of smokers attending the taster session (Intervention
group only); (2) perception of the taster session; (3) per-
ception of the personal invitation letters; and (4) reasons
for non-attendance at the taster session and barriers to
attendance at the NHS services.
Health economic measures The economic component
will estimate the cost of providing the interventions, using
primary cost data from an NHS and personal social ser-
vices (PSS) perspective as recommended by National Insti-
tute for Health and Clinical Excellence (NICE) guidance
[29]. We will also measure patients’ use of health and so-
cial care services using comprehensive service use ques-
tionnaires as employed on a number of other trials in the
addiction field. Quality-adjusted life years (QALYs) will be
calculated from the EQ-5D questionnaire [30] and com-
bined with cost data in the cost-utility analysis.
Evaluation procedure
Research interviewers, independent from the service
providers, will conduct follow-up interviews 6 months
after the date of randomisation, by telephone, to assess
attendance at the services, current smoking status, daily
cigarette consumption, reasons for non-attendance, and
barriers to attendance in all participants. Interviewers
will make a maximum of 10 attempts to contact the22 Week 24 Week 31 to 38 Weeks 37 to 49
tailored 
 sent to 
ers
Taster session 
following reminder 
invitations held
6-month follow-up 
questionnaire by 
telephone
Collection of 
salivary cotinine
for validation of 
smoking status
Collection of data 
from SSS  for 
validation of 
attendance
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before classifying the participant as lost to follow-up.
All self-reported attendance at the NHS SSS will be
validated by records of attendance. All participants will
be asked if they attended a taster session; those answer-
ing negatively will be asked if they know or have spoken
to anyone who attended a taster session. Participants
claiming 7-day abstinence will be asked to provide a sal-
ivary cotinine sample to bio-chemically validate 7-day
point prevalent smoking cessation at a 6-month follow-
up [31]. Samples will be obtained by post using a saliva
sample kit. As the cotinine content can be affected by
continued use of NRT, usage at the time the sample is
given will be assessed by questionnaire. A £5 Marks and
Spencer voucher will be included with each kit, and a
further £5 voucher sent upon return of the kit to maxi-
mise kit return [32].
Attendance at the NHS SSS could be taken up at any
time during the 6 months between receipt of the invitation
(Intervention Group) or standard letter (Control Group)
and the 6-month follow-up. Hence, at 6 months some par-
ticipants could be at varying stages of completion of a
course, and at varying stages of a quit attempt. Therefore
secondary outcome measures include self-reported pro-
longed abstinence of periods of up to 24 weeks, a measure
that can also apply to those not attending the NHS service.
We will also assess 4-week abstinence in those attending
the SSSs using the NHS monitoring data collected by
smoking cessation advisors. These monitoring records can
be used to compare quit rates of clients proactively
recruited through our intervention with those of other
attendees at the NHS SSSs.
We will measure perception of the personal invitation
letters and of the taster session using measures from
our previous trials of tailored feedback adapted to apply
to the personal invitation letters [21,33]. Reasons for
non-attendance at the taster session and barriers to
attendance at the NHS services will be assessed using
open rather than closed questions to ensure that respon-
dents are not inhibited in their answers to those which
the researchers consider to be relevant. All process
measures will be included in the telephone follow-up
interview 6-months after the date of randomisation.
Perception of the taster session will also be assessed by
an evaluation form immediately after each session.
Sample size and power calculations
Recent evidence from the study of Murray and collea-
gues suggests that attendance at NHS services can be
increased by 7.7% (from 8.9% to 16.6%) using a proactive
intervention [18]. To detect an effect of this size at 90%
power and alpha of 0.05 would require a sample of 420
participants per group. However, in the absence of other
similar trials, we might assume that the uptake ofservices in those who receive the tailored letter and
the taster session could be lower than that reported by
Murray. Hence, assuming an estimated increase of 4.6%
(from 8.9% to 13.5%, OR 1.65) we would require 1,029
participants per group, 2,058 in all, to detect this differ-
ence as statistically significant at the 5% level with 90%
power.
Practices will be recruited from 10 different NHS SSSs.
The taster sessions in each SSS will be run by the same
four advisors comprising 10 therapist clusters. Thus be-
fore adjusting for clustering we would expect 103
patients per cluster. While the intervention is manua-
lised and structured training run to reduce the variability
between the interventions delivered in each SSS, to ac-
count for any persistent therapist effects that will be ap-
plied to those randomised to receive a taster session,
assuming a therapist intraclass correlation coefficient
(ICC) of 0.005 (in the absence of any published data),
and a therapist cluster size of 103, requires further infla-
tion of our existing sample size by a factor of 1.51 only
in the Intervention group where the effects will occur.
Thus, 1,554 will receive the tailored letter and taster ses-
sion, 2,583 participants in total.
The same RCT [18] found validated quit rates at
6 months of 4% versus 2.2% (a difference of 1.8%) in the
Intervention and Control Groups. With 2,583 partici-
pants (distributed between Intervention and Control
groups as described above), we will be able to demon-
strate a slightly larger difference of 2.2% with 80%
power.Planned recruitment rate
Practices generally identify 13% to 22% of their patients
as smokers [34], depending on the characteristics of the
patient population, and the accuracy and completeness
of the records. Therefore six practices in each of 10 SSSs
with a list size of > 4,000 would give approximately
240,000 patients and, assuming a conservative smoking
prevalence of 15% in patients aged 16 years and over,
36,000 smokers. Based on previous studies [18,26] we
estimate a response rate of 7% from smokers motivated
to quit, from two mailings. This will secure 2,520 partici-
pants, meeting the requirements of the sample size
calculation.
Initial recruitment to the pilot phase of the RCT was
planned in 12 practices in two SSSs. Using the assump-
tions above this would have secured 504 participants.
We then planned to proceed to the full RCT to recruit a
further 2,016 participants in a further eight SSSs after
conducting a first stage analyses to confirm that: (1) a
7% response rate from participants giving consent and
agreeing to randomization has been achieved; and (2) a
preliminary analysis suggesting a difference in uptake of
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Control groups greater than zero.
Based on previous studies using follow-up by tele-
phone [21], approximately 20% to 25% attrition is
expected.
Statistical analysis
Pilot phase
Recruitment during the pilot phase was estimated to be
approximately 20% of the total sample. The methods
used in the pilot phase are essentially the same as those
used in the full trial to enable combination of the data
from both phases for analysis. However, lessons learnt
on recruitment strategies from the pilot phase will be
applied to the main trial.
Main analysis
Baseline characteristics of participants will be summar-
ized. Chi-squared tests will compare binary outcomes
between the Intervention and Control Groups (for ex-
ample, attendance at the services, point prevalent abstin-
ence), with logistic regression to take into account any
imbalance in important baseline characteristics between
the groups; these factors will be nominated prior to
examination of the trial data. Continuous variables (for
example, reduction in daily cigarette consumption) will
be compared with the two-sample t-test, and with mul-
tiple linear regression to account for important charac-
teristics. Odds ratios for differences in means or
medians (as appropriate) will be quoted together with
their 95% confidence intervals. Loss to follow-up after
randomisation will be reported. Analyses will be based
on intention-to-treat (that is, those lost to follow-up will
be assumed to be still smoking) with sensitivity analysis
to examine the influence of loss to follow-up.
Specifically we will conduct an analysis on multiple
imputed missing outcome data at 6 months. The imput-
ation model will use observed baseline covariates and
outcome data. Estimates of the attendance at NHS
smoking cessations SSS at 6 months will be compared
between the Intervention and Control groups. A sensi-
tivity analysis will then be possible based on our worst
case imputation (that is, our assumption of non-
attendance for all those lost to follow-up) [35,36]. A lo-
gistic regression model will be used to adjust for baseline
sociodemographic variables. The general practice will be
included in the model as a random effect. In addition to
the intention-to-treat analysis we shall estimate the
causal effect of the intervention using CACE, the com-
plier average causal effect estimator (or equivalently, an
instrumental variables estimator) [37]. In the CACE
analysis we will consider attendance at the first NHS
smoking cessation service in terms of a binary variable
as well as a dose effect (that is, the number of sessionsattended in total). We shall take a parallel approach
to the analysis of secondary outcomes (for example,
smoking cessation).
Planned subgroup analyses
We will examine the predictors of attendance in the
two groups (that is, in those proactively recruited and
those self-referred after standard advertising). We will
also explore any delayed effect of sending repeat remin-
ders to smokers on the uptake of service, and any dif-
ferences in attendance due to seasonal variations. We
are aware, however, that the study will be inadequately
powered to do any detailed subgroup analyses on spe-
cific groups of smoker such as those of lower socioeco-
nomic status and hence we will merely explore for
trends.
We will also estimate if the quit rate in the recruited
sample is similar to that of services based on figures
from previous quarterly returns.
Economic analysis
The economic analysis will measure and value the costs
of delivering the interventions and the wider changes in
health and social care costs. Intervention costs will be
calculated by computing the costs of the programmes,
which will include materials used in the programmes
and the time spent by health professionals in service de-
livery. These costs are then attributed to patients receiv-
ing the interventions. Patients’ wider utilisation of health
and personal social services resources in the preceding
period are also recorded at baseline and follow-up. The
total costs of the health and personal social services
resources are calculated using national unit costs from a
range of published sources.
The total costs to health and personal social services
are calculated, as recommended by NICE guidance [29],
and combined with outcome data to generate the
estimated cost per QALY. QALYs are derived from the
EQ-5D questionnaire [30] administered at baseline and
follow-ups. The probability of the tailored letter being
cost-effective over and above the generic letter at NICE
QALY threshold values will be explored using cost-
effectiveness acceptability curves [38].
Proposed frequency of analyses
An analysis will be conducted on completion of the
follow-up to the pilot study. Following this there will be
no further analyses until full recruitment and follow-up
has been achieved.
Service user involvement
The trial is embedded in the NHS through the inclusion
of a Stop Smoking Service Manager as a co-applicant,
who is involved in the design, conduct, and analysis. In
Consort diagram of the flow of  participants through the trial
SSSs (n=2)
Total P ractices recruited (n=7)
List size (range=4251 to 16721)
Total list size = 65,785
Total Smokers identified = 11,202 (17%)
Willing but not eligible=149
Not ready to quit=53
Attended SSS in last year=38
Recently quit=44
Pipe/cigar smokers=14
Smokers enrolled in trial=426 (5.5%)2
Randomised to Intervention Group = 259
Sent personalised letter with risk information 
and invitation and appointment to taster session
Randomised to Control Group =167
Sent standard generic letter advertising the 
services
Completed 6-month telephone follow-
up interview = 186 (71.8%)
Completed 6-month telephone follow-
up interview = 115 (68.9%)
Total potentially eligible smokers sent invitation and questionnaire = 7941(12%)
Exclusions = 2654
by GP = 997
duplicate address = 1657
Not replied = 6814
Total Response = 1127 (14.2%) 1
Refused = 552
Wrong address = 17
Non smoker = 590 
Total sent invitation to participate and questionnaire = 8548(13%)
Attended taster session = 89 (34.4%)
Attendance at NHS services measured 
(data not yet available) Attendance at NHS services measured (data not yet available)
Validation of smoking status by salivary 
cotinine sample (data not yet available)
Validation of smoking status by salivary 
cotinine sample (data not yet available)
Pilot phase (actual figures) Full trial phase (projected figures)
SSSs (n=16)
Practices with list size >6500 (n=96) 
Total list size = 624000
Total smokers identified and sent invitation to participate 
and questionnaire (12% after exclusions) = 74880
Total Response rate (14%) = 10480
Smokers willing and eligible to participate (5.5%) = 4120
2472 Participants randomised to 
Intervention Group. Sent personalised 
letter with risk information and invitation 
with appointment to taster session
1648 Participants randomised to Control 
Group. Sent standard generic letter 
advertising the services
Measure attendance at taster session 
Measure attendance at NHS services Measure attendance at NHS services 
6-month telephone follow-up interview 
Estimated completers=1730 (70%) 
6-month telephone follow-up interview 
Estimated completers=1152 (70%) 
Validate smoking status by salivary 
cotinine sample
Validate smoking status by salivary 
cotinine sample
1
 Of total potentially eligible and sent invitation = 7941
2
 Of total potentially eligible and sent invitation minus total willing but not eligible = 7792
Figure 2 Consort diagram of the flow of participants through the trial.
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Camden has been invited onto the Trial Management
Group and is involved in the study from the design stage
onwards. Thus, the interests of all parties and the views
of the public are fully represented in the conduct of the
study.Discussion
Personal risk information, generated by computer, is a
simple and inexpensive intervention which, if the trial
demonstrated benefit, could be widely replicated and
delivered cost-effectively to a large proportion of the
smoking population, prompting more quit attempts, and
increasing referrals to NHS specialised smoking cessa-
tion services. The programme could be made available
to practices, these letters, tailored to the requirements of
each individual, offering GPs and practice nurses an effi-
cient way of integrating referrals to the smoking cessa-
tion service into a busy primary care practice. Moreover,
the introduction of a taster session delivered by existing
NHS smoking cessation advisers could be easily imple-
mented into the practice at a small additional cost. A
modest success rate could have a large effect on uptakeof services given its recruitment potential, and make a
valuable contribution to public health by lowering smok-
ing prevalence.
Trial status
The pilot phase of the trial has been completed. Recruit-
ment was carried out between February and April 2011,
in Camden and Oxfordshire, both areas with high pro-
portions of ethnic minorities, and the follow-up was
completed between September and December 2011.
The aims of the pilot phase were to assess the feasibil-
ity of the procedure (that is, searching medical records
and mailing screening questionnaires, the generation of
the tailored letters, the randomisation and delivery of
the intervention), to ascertain recruitment rates and to
assess the uptake of the taster sessions, and to establish
that the uptake of smoking cessation services in the
Intervention group was greater than in the Control
group (that is, the difference in proportions, intervention
minus control, is greater than zero).
Successful achievement of these aims has allowed us
to proceed to the full trial. Recruitment slightly below
the original estimate led to a revision of the planned re-
cruitment rate from 7% to 5.5%, and to a revision of the
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ing, in order to meet the target sample size (Figure 1).
Changes due to additional funding
As a result of the successful recruitment on the study,
additional funding was approved in July 2012 to carry
out additional work which will build on the study and
maximise its utility. The following changes have been
implemented:
(1) In addition to the original primary outcome (the
proportion of people entering the smoking cessation
service over a period of 6 months), 7-day point preva-
lent abstinence at the 6-month follow-up, validated by
salivary cotinine is now also included as a co-primary
outcome. This will allow us to assess whether this
intervention also translates to increased quit rates, and
if the quit rates in people attending as a result of this
intervention differ from the usual quit rates in NHS
services. This change necessitated a recalculation of the
sample size needed. Assuming quit rates of 4% versus
2.2% in the Intervention and Control groups (mimick-
ing the findings of Murray et al. [18]) an 80% increase
in the sample size is required, to 1,793 in the Control
group and 2,707 in the Intervention group (assuming
the same therapist effect as the original protocol), a
total of 4,500. A sample of this size gives 85.4% power
to detect a difference of 1.8% at the 5% significance
level. The same sample size would have 95% power to
detect the difference between quit rates of 4.4 and 2.2%
(doubling of the quit rate). Based on current recruit-
ment figures, we estimate that an additional eight SSSs
(48 GP practices) will recruit 2,060 participants, giving
a total of 4,580 and meeting the requirement of the
power calculation.
(2) In the pilot phase of the study we assessed barriers
to attendance at the NHS services using an open ques-
tion. For the remainder of the study we will use the
Treatment Barriers Questionnaire, a 40-item measure of
reasons for not entering smoking cessation programs
that has been recently validated on a low socioeconomic
population in the USA [39]. This questionnaire will
allow us to assess different aspects of smokers’ decisions
to attend a group or therapy session and highlight any
misconceptions or lack of awareness of the service
offered. It will also allow us to explore associations
with demographic and dependence factors, as well as
validating the questionnaire on a UK population. The
Treatment Barriers questionnaire will be mailed to ap-
proximately 3,500 participants who report not attending
the SSS and who agree to complete an additional
questionnaire.
(3) Taster sessions are being recorded to ensure fidelity
to the protocol. Assessing this fidelity can help to ad-
dress factors that might have impacted on subsequentattendance and quit rates. Full analysis of the recording
of the Taster sessions, using thematic analysis, will be
carried out to allow the exploration of differences in
style and delivery of the intervention and their impact
on subsequent attendance and quit rates.
Recruitment to the main trial is now under way in a
further 16 areas that are representative of the English
SSS. The target of 4,500 participants is expected to be
reached by October 2013.
The flow of participants in the pilot phase and the
planned flow of participants through the main trial are
summarised in Figure 2.Additional file
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